Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.Reiki Nishimura, Kazuo Tamura, Fumie Matsuo et al.|PubMed|2012Cited by 3